$First Wave BioPharma(FWBI)$ First Wave BioPharma fell more than 16% in premarket trading after Co. said a Phase 2 study of an enhanced formulation of its adrulipase drug candidate likely missed its primary efficacy endpoint. AInvestPro
| 发布于: | 雪球 | 转发：0 | 回复：0 | 喜欢：0 |
$First Wave BioPharma(FWBI)$ First Wave BioPharma fell more than 16% in premarket trading after Co. said a Phase 2 study of an enhanced formulation of its adrulipase drug candidate likely missed its primary efficacy endpoint. AInvestPro